Mazdutide – A Dual Receptor Agonist That Promotes Weight Loss and Blood Glucose Control
What Is Mazdutide?
Mazdutide is a new, first-of-its-kind medicine that has been developed for the treatment of obesity and type 2 diabetes. It was approved for use in China in June of 2025, and it can be administered by injection once weekly.
How Does Mazdutide Work?
Mazdutide is a dual receptor agonist, meaning it binds to two different receptors, GLP1R (glucagon-like peptide 1 receptors) and glucagon receptors. This combination that targets receptors is what makes mazdutide unique. GLP–1 is a hormone normally produced by the body in response to eating a meal, and which influences:
- Eating behaviour
- Metabolism
- Insulin secretion.
- Glucagon is normally secreted in response to low blood glucose levels, fasting, or
exercise, to alter metabolism and energy expenditure.
Mazdutide works by:
- Activating GLP–1 receptors
- Activating glucagon receptors
Activating GLP–1 receptors
Mazdutide agonises GLP–1 receptors regardless of whether a meal has been ingested or not. It acts on GLP–1 receptors in the pancreas to stimulate insulin secretion when glucose levels are elevated, and affects GLP–1 receptors in other parts of the body as well, such as the brain and intestines [1].
Activating glucagon receptors
By also activating glucagon receptors, the body responds as though it is in a fasted state, which alters the way energy is metabolised. Activation causes glucose to be released from the liver when blood sugar levels are low, with the increase in blood glucose being counterbalanced by GLP1R agonism. More importantly, the release of glucose is accompanied by an increase in energy expenditure [2].
Mazdutide Benefits
By binding to both GLP–1 receptors and glucagon receptors, Mazdutide brings about the following
benefits:
- Reduced appetite and prolonged feeling of satiety
- Increased control over blood glucose levels
- Increased energy expenditure and weight loss
Reduced appetite and prolonged feeling of satiety
GLP1R activation is responsible for this benefit. It promotes the feeling of satiety, meaning that the desire to eat more food is reduced. Gastric emptying is delayed, so hunger will return later than normal after eating. These combined effects help reduce calorie intake and promote weight loss.
Increased control over blood glucose levels
Increased energy expenditure and weight loss
Mazdutide Side Effects
• Nausea
• Vomiting
• Diarrhoea
• Bloating
• Decreased appetite
How Mazdutide Compares to Other Similar Drugs
Why Buy From Us?
- High quality backed by documentation
- Tamper–proof packaging for product integrity
- Customer support from experienced staff
- Fast and discreet shipping worldwide
- Competitive bulk pricing available for institutions and labs
Conclusion
References
- Müller TD, Finan B, Bloom SR, et al. Glucagon–like peptide 1 (GLP–1). Mol Metab. 2019;30:72–
130. doi:10.1016/j.molmet.2019.09.010 - Winther JB, Holst JJ. Glucagon agonism in the treatment of metabolic diseases including type
2 diabetes mellitus and obesity. Diabetes Obes Metab. 2024;26(9):3501–3512.
doi:10.1111/dom.15693 - JIANG H, JI L, ZHANG Y, et al. 1866–LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults
with BMI of 30 kg/m2 or more. Diabetes. 2024;73(Supplement_1):1866–LB.
doi:10.2337/db24–1866–LB - Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese
overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289.
doi:10.1038/s41467–023–44067–4 - Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With
Type 2 Diabetes: A Randomized, Double–Blind, Placebo–Controlled Phase 2 Trial. Diabetes
Care. 2024;47(1):160–168. doi:10.2337/dc23–1287 - Ji L, Jiang H, Bi Y, et al. Once–Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
N Engl J Med. 2025;392(22):2215–2225. doi:10.1056/NEJMoa2411528 - Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP–1 and glucagon receptor dual agonist
mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A
randomised, placebo–controlled, multiple–ascending–dose phase 1b trial.
eClinicalMedicine. 2022;54:101691. doi:10.1016/j.eclinm.2022.101691 - Wilding JPH, Batterham RL, Calanna S, et al. Once–Weekly Semaglutide in Adults with
Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 - Trinh H, Donovan A, McAdam–Marx C. Real–world effectiveness of tirzepatide versus
semaglutide for weight loss in overweight or obese patients in an ambulatory care setting.
Diabetes Obes Metab. 2025;27(6):3523–3525. doi:10.1111/dom.16343
Reviews
There are no reviews yet.